grants_govPAR-25-059
Open
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
- Response deadline
- Oct 20, 2027 Due in 369 days
- Date posted
- Oct 22, 2024
- Source
- Open notice
Description
This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.
Classifications
- NAICS93.853
Documents (1)
- DownloadPAR-25-059-Full-Announcement.htmltext/html422 B
Contacts
- grantsinfo@nih.gov301-402-2541
Similar contracts
- Mechanistic Evaluation of Therapeutic Targets derived from Treatable Traits to Improve CNS Outcomes in People with HIV (R21/R33 Clinical Trial Not Allowed)Due Oct 28, 2027
- NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed)Due Apr 17, 2029
- NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)Due Mar 9, 2029
- Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed)Due Sep 28, 2026
- NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)Due Apr 5, 2029
- NINDS Child Neurology Career Development Program (CNCDP) (K12 - Clinical Trial Not Allowed)Due Jul 10, 2026